NASDAQ · Biotechnology
CNSP (CNSP) Stock
$5.40
+0.75%
NASDAQ: CNSP
Healthcare
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
CNS Pharmaceuticals CFO, Steve O'Loughlin, Highlights Company's Recent $22.5M Financing in Virtual Investor "What This Means" Segment
ACCESS Newswire · Jun 8, 2026
CNS Pharmaceuticals CEO, Rami Levin, Participates in Virtual Investor CEO Connect Segment Highlighting Company's Recent Strategic Transformation Progress
ACCESS Newswire · May 20, 2026
CNS Pharmaceuticals Registers 9.79 Million Shares for Selling Holders
MT Newswires · May 19, 2026
Forget the 242% Biotech Meme. This Brain Cancer Stock Has a $38 Analyst Target and Trades at $6
24/7 Wall St. · May 14, 2026
CNS Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Strategic Transformation Progress
ACCESS Newswire · May 14, 2026
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Insiders Held0.49%
Institutions Held12.51%
Institutions Float Held12.57%
Peer Comparison
About CNSP
CNSP is led by CEO Rami Levin, employs 4 people, headquartered in US, publicly traded since 2019.
CNSP stock trades at $5.40 with a market capitalization of $3.10M. The stock is valued at a price-to-earnings (P/E) ratio of -0.14, price-to-book of 0.59, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.90 and $12.36, and currently trades 56.3% below its 52-week high.
On profitability, CNSP generates a return on equity (ROE) of -320.00%, return on capital employed of -320.00%, an operating margin of 0.00%, a net profit margin of 0.00%.